CALCRL and migraine disorder: In this context, we evaluated comorbid symptoms of anxiety, depression, and fatigue at baseline and 3 months after starting a treatment with monoclonal antibodies (mAbs) acting on the CGRP (Fremanezumab and Galcanezumab) or its receptor (CGRPR) (Erenumab) in a cohort of 77 subjects with a diagnosis of migraine resistant to traditional drug prophylaxis either high-frequency EM (HFEM > 8 headache days/month) or CM with or without MOH.